Medicis Aesthetics SWOT Analysis and SWOT

Threats

Luckily, Medicis Aesthetics' capital position as a subsidiary of Medicis Pharmaceutical Corporation also enables it to better weather external threats to the company, which certainly exists for the industry as a whole. Threats of litigation are a very real factor of how this industry does business, especially with certain product lines. In addition, the industry is now facing the threat of a prolonged recession, which many analysts claim we are only in the beginnings of. If this proves to be the case, Medicis Aesthetics and its competitors will be faced with an ever-shrinking consumer pool. This will make competition fiercer and make profitability highly dependent on materials and labor costs.

Product Comparison

Two of Medici Aesthetics' most popular and currently profitable products are Restylane and Perlane, both of which are dermal fillers (non-surgical wrinkle removers) composed of hyaluronic acid. Though patented and using a relatively unique mechanism to achieve its results, these two related products are far from the only dermal fillers or medical wrinkle removal products/systems/procedures on the market, making competition quite fierce in this arena.The same is true of its Triaz anti-acne medicated foaming wipes, though the company's Solodyn, an oral antibiotic for the treatment of acne and acne infections in adolescents and adults, is more unique and faces less competition from similar products in the industry manufactured by competing organizations.

Price Comparison

These patents do not come cheaply, whether or not there are similar products in existence as well, but all of the companies in this industry face the same prohibitive costs and limitations in customer potential. These forces are likely largely responsible for the generally equitable prices found between Medicis Aesthetics pharmaceuticals and other available products and treatments for the same conditions. The market forces are very much in effect in this industry, where all spending is ultimately discretionary, and no company can afford to be out priced by another. Specific precuts, however, notably the two dermal fillers mentioned above, have retained a market niche and built brand loyalty, allowing for premiums to be charged for the product......